VRTX · News · 20260811N
Revenue Performance and Mix
VERTEX PHARMACEUTICALS INC / MA · 2026-08-11 · Importance 83 · Surprise 60 · In source text
Vertex reported Q2 2026 revenue of approximately $3.3 billion, exceeding analyst estimates. Revenue growth was driven by the cystic fibrosis portfolio and newer products including CASGEVY and JOURNAVX. The company raised its 2026 revenue guidance to $13.10–$13.20 billion.
Key facts
- MarketBeat reported Vertex Pharmaceuticals Q2 revenue of $3.33 billion and that earnings per share slightly missed estimates. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | realized | — | MarketBeat reported Vertex Pharmaceuticals Q2 revenue of $3.33 billion and that earnings per share slightly missed estimates. |